Vancouver, British Columbia--(Newsfile Corp. - November 21, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Prof. Mirela Dellbegovic, FRSE to the Scientific Advisory Board effective on 19 November, 2024.

Stephen Van Deventer, CEO of BioGene, commented:

"We are honored to welcome Professor Mirela Delibegovic to our Scientific Advisory Board. Mirela's extensive research in obesity and diabetes physiology and signaling, coupled with her leadership in translational discovery, will provide invaluable insights as we advance our therapeutic programs. Her expertise aligns seamlessly with BioGene's mission to develop innovative solutions for metabolic health challenges."

About Professor Mirela Delibegovic:

Professor Delibegovic is a distinguished academic and entrepreneurial research leader in biomedical sciences. She currently holds the Regius Chair of Physiology at the University of Aberdeen and serves as the Director of the Aberdeen Cardiovascular and Diabetes Centre. With over 25 years of experience in the cardiometabolic field, her research focuses on the molecular mechanisms underlying diabetes, obesity, and their complications, with an emphasis on translational discovery and therapeutic development.

Throughout her career, Professor Delibegovic has initiated and developed constructive collaborations leading to key publications, significant sustainable funding, and impactful translational research outcomes. Work developed through these collaborations was recently highlighted by the United Nations Academic Impact publication as the example of a successful collaboration between academia and industry. She has been recognized with numerous awards, including being elected a Fellow of the Royal Society of Edinburgh (FRSE) in 2022. Her leadership extends to various national and international committees, reflecting her commitment to advancing biomedical research and innovation.

Professor Delibegovic remarked on her appointment:

"I am delighted to join BioGene's Scientific Advisory Board and collaborate with a team dedicated to addressing critical unmet medical needs in cardiometabolic health. I look forward to contributing my expertise to support BioGene's innovative therapeutic initiatives."

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

About BioGene Therapeutics Inc.

BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5% R&D tax cashback incentive. This subsidiary supports ongoing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.

On Behalf of the Board of Directors,

PreveCeutical Medical Inc. & BioGene Therapeutics Inc.

"Stephen Van Deventer"
Chairman & Chief Executive Officer

Forward-Looking Statements:

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.